BLOG

endpoints

Betting on cell memory, AbbVie pays Immunome $30M upfront to further antibody research

AbbVie has tapped Immunome’s discovery platform in a heavily backended partnership and option agreement in a bid to discover 10 antibody-target pairs from three as-yet-unnamed tumor types.